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ABSTRACT  1 
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening 2 
conditions with high morbidity and mortality. Supportive care management of SJS/TEN is highly 3 
variable. A systematic review of the literature was performed by dermatologists, 4 
ophthalmologists, intensivists and gynecologists with expertise in SJS/TEN to generate 5 
statements for supportive care guideline development. Members of the Society of Dermatology 6 
Hospitalists (SDH) with expertise in SJS/TEN were invited to participate in a modified, online 7 
Delphi-consensus. 9-point Likert scale questionnaires regarding 135 statements were 8 
administered. The RAND/UCLA appropriateness method was employed to evaluate and select 9 
proposed statements for guideline inclusion; statements with median ratings of 6.5-9 and 10 
disagreement index ≤1 were included in the guideline. For the final round, the guidelines were 11 
appraised by all the participants. An evidence-based discussion and recommendations for 12 
hospital setting and care team, wound care, ocular are, oral care, urogenital care, pain 13 
management, infection surveillance, fluid and electroly e management, nutrition and stress ulcer 14 










CAPSULE SUMMARY 24 
• Supportive care management of SJS/TEN in practice is highly varied. 25 
• The Society of Dermatology Hospitalists presents evidence-based practice guidelines for 26 
hospital setting and care team, wound care, ocular are, oral care, urogenital care, pain 27 
management, infection surveillance, fluid and electroly e management, nutrition and stress 28 




















Stevens-Johnson syndrome/toxic epidermal necrosis (SJS/TEN) spectrum disease (i.e., SJS, SJS-48 
TEN overlap, and TEN) is a rare, severe cutaneous reaction affecting 1.6 to 9.2 patients per 49 
million annually in the United States.1-6 With mortality rates between 15% and 49%,7-9 early 50 
intervention with intensive supportive care is criti al, yet the care implemented in practice is 51 
highly variable.10 Standardized SJS/TEN management guidelines are a pressing unmet clinical 52 
and research priority. 53 
 54 
METHODS 55 
Eleven topics were developed within the scope of the guidelines (Table 1). For each topic, 56 
PubMed, EMBASE, CINAHL, the Cochrane Library, and clini altrials.gov were searched for 57 
meta-analyses, clinical trials, open studies, case seri s, and case reports through November 2018. 58 
Articles not written in English were excluded. The search terms and strategies are detailed in 59 
eAppendix1. The authors identified additional references from manuscript citations, performed 60 
detailed evaluation, summarized the literature, and provided level of evidence and strength of 61 
recommendations, as indicated in eAppendix2.  Prior guidelines on SJS/TEN were also 62 
evaluated.11-16  63 
Experts in SJS/TEN from the Society of Dermatology Hospitalists (SDH) were invited to 64 
participate in the modified Delphi process (eAppendix3) and to evaluate the level of 65 
appropriateness of 135 statements regarding supportive care of patients with SJS/TEN.  66 
Using the RAND/UCLA appropriateness method,17 each statement was evaluated by the 1-to-9 67 
appropriateness rating scale and by the level of disagreement, as measured by a disagreement 68 
index (DI). A median appropriateness value of 1≤median<3.5 was considered “inappropriate;” 69 
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3.5≤ median<6.5 “uncertain;” and 6.5≤median≤ 9.0 “appropriate.” Descriptive statistics were 70 
calculated for each item during each round and present d with a histogram (eAppendix4). R 71 
version 3.6.1 (R Core Team 2019, Vienna, Austria) ws used to perform all analyses. 72 
 73 
RESULTS  74 
The SDH supportive care practice guidelines for the management of SJS/TEN in adults are 75 
presented in Table 2. 76 
 77 
DISCUSSION 78 
Hospital setting and care team  79 
Specialized care with a multidisciplinary approach is essential to the evaluation and treatment of 80 
patients with SJS/TEN.11,13,14,16 Dermatologists should directly participate in patien  81 
management, with input from other specialists with expertise in management of the 82 
complications of complex epidermal loss, such as fluid management, wound care, and 83 
mechanical ventilation.18-20 Several small uncontrolled studies have shown decreased mortality 84 
with early transfers to burn units or intensive care units (ICU). 21-28 The SDH expert panel 85 
recommends care take place in a medical or burn ICU setting, with staff trained in the care of 86 
patients with SJS/TEN. A private room with temperatu e and humidity control and at least 1:1 87 
nursing care is recommended.  88 
 89 
Wound care  90 
Wound care for SJS/TEN generally follows current practices in burn management, as strong 91 
evidence specific to SJS/TEN is lacking.29 Percentage body surface area (BSA) of detachable 92 
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epidermis is integral to patient prognosis and disease progression.30 Unlike burn guidelines, 93 
which recommend surgical or high-velocity saline debridement of detached epidermis,12,31,32 the 94 
dermatologic SDH expert panel favors a conservative approach to preserve detached epidermis 95 
as a biologic dressing, reflecting the different underlying mechanisms involved with SJS/TEN 96 
and burn injury.33 Anti-shear strategies, such as limiting dressing changes, using an air-fluidized 97 
bed, and selecting non-adherent dressings, are recommended.11,16,34 Lysis and careful drainage of 98 
large or painful bullae may be performed for comfort only. Gentle cleansing, consisting of sterile 99 
water or dilute chlorhexidine with dressing changes, is advised.35 Application of an emollient 100 
such as petrolatum jelly to the skin enhances barrier function, reduces transcutaneous water loss 101 
and encourages re-epithelialization.11,36  Alternatively, modern non-adherent, silver-impregnated 102 
primary dressings are recommended for their antibacteri l properties, reduced requirement for 103 
dressing changes, and improved patient comfort.29,37-41 Secondary absorptive dressings should be 104 
used to control exudate. 105 
 106 
Ocular care  107 
Ocular involvement may precede or follow cutaneous disease and occurs in 50-90% of 108 
patients.27,42-48 Acute ocular findings range from conjunctival hyperemia to loss of the entire 109 
ocular surface and eyelid margin epithelium.45,49,50 The severity of ocular involvement disease 110 
has not been reliably correlated with the severity of skin disease or SCORTEN.48,49,51,52  111 
The SDH expert panel recommends ophthalmic evaluation of all patients with suspected 112 
SJS/TEN, even if there is no apparent ocular involvement. Examination should occur during the 113 
initial assessment, daily until findings have stabilized, and then the frequency is determined on 114 
an individual basis. The entire ocular surface and eyelid margins should be examined with eyelid 115 
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eversion, eye rotation and fluorescein staining. Resting eyelid position should be assessed so 116 
lagophthalmos can be promptly addressed. Saline may be used to remove loose debris and 117 
appropriate tools used to lyse adhesions during daily exams. Grading of ocular findings may aid 118 
in medical and surgical decision making (e.g. eAppendix5).46 119 
Amniotic membrane transplantation (AMT) has shown to mitigate long-term ocular 120 
complications  in multiple studies.51,53-59 AMT should be offered to patients with significant 121 
conjunctival, corneal or eyelid margin epithelial defects. If AMT is indicated and not available, a 122 
hospital transfer should be considered. Amniotic membrane should cover the entire affected 123 
surface including eyelid margins and may need to be replaced over time. 124 
Limited data address the use of topical therapies, including lubricants, anti-inflammatory agents 125 
and anti-microbial agents.15,49,60 For patients without acute ocular involvement, prese vative-free 126 
artificial tears (AT) should be considered (e.g. AT4 x/day). Any degree of ocular involvement 127 
should prompt high-frequency AT (e.g. AT every 1-2 hours).  Topical corticosteroids are used to 128 
ameliorate ocular inflammation and may improve visual outcomes.15,46,59,62 For any degree of 129 
ocular inflammation, a topical corticosteroid drop should be applied to the ocular surface (e.g. 130 
prednisolone acetate 1%, 2-6 x/day), and a corticoster id ointment should be applied to the 131 
eyelids (e.g. fluorometholone 0.1%, 2-6 x/d). There is limited evidence to guide the use of 132 
prophylactic topical antibiotics; however, for patients with ocular epithelial defects, a broad-133 
spectrum topical antibiotic (e.g. Moxifloxacin 0.5%, 3 x/day) should be used. If an ocular 134 





Oral care 139 
Oral involvement occurs in 93 to 100 % of patients with SJS/TEN, resulting in pain, impaired 140 
oral intake, and poor oral hygiene.43,63 Long-term complications include sicca syndrome in up to 141 
40% of patients and scarring.64-66  142 
All patients with SJS/TEN should have an oral cavity exam on initial presentation and daily 143 
thereafter. The use of topical therapies for treating oral involvement in acute SJS/TEN has been 144 
adapted from studies in patients with autoimmune blistering diseases involving the oral mucosa, 145 
chemotherapy-induced mucositis, and oral graft-versus-host disease (GvHD).67-71 To provide 146 
short-term pain relief and facilitate oral intake, a mouthwash containing a topical anesthetic 147 
agent such as lidocaine is recommended.63 Topical coating agents have been recommended to 148 
reduce pain and facilitate healing by covering mucosal ulcerations, such as hydroxypropyl 149 
methylcellulose film-forming agents (e.g., Zilactin®), Gelclair®, and Amphojel®.68  150 
Oral rinses increase clearance of debris, promote oral hygiene, and improve patient comfort.68 151 
Antiseptic oral agents are preferred by the SDH expert anel, with a recommendation to consider 152 
diluted chlorhexidine.72 Ultrapotent topical corticosteroids (e.g., clobetasol gel or ointment 153 
(0.05%) with or without adhesive bases such as carboximethyl or hydroxyethyl-cellulose, three 154 
to four times a day) have been shown to be beneficial in the management of patients with erosive 155 
diseases of the oral mucosa73,69,74-76 and are recommended by the expert panel. Dexamethasone 156 
mouth rinse (0.1 mg/mL) or clobetasol propionate 0.05% in aqueous solution, are alternative 157 





Urogenital care  162 
Urogenital involvement occurs in approximately 70% of women78-80 and men80 with SJS/TEN, 163 
resulting in erosions of the scrotum/labia, penis/vulva, dysuria, hematuria, urinary retention, and 164 
long-term sequelae such as urethral stenosis and scrring, xerosis, phimosis, dyspareunia, 165 
chronic pain, bleeding, sexual dysfunction, infertility, and anxiety.78-89 166 
The urogenital tract of all patients with SJS/TEN should be examined upon initial assessment 167 
and daily during hospitalization, ideally by a gynecologist, urologist, or urogynecology 168 
specialist. The efficacy of treatment strategies has not been adequately studied. Emollients, such 169 
as petrolatum, are commonly used to protect inflamed ucosa, reduce adhesion formation, and 170 
facilitate healing.16,80,85 Ultrapotent topical corticosteroids applied to genital lesions during the 171 
acute phase may be helpful.85 If there is clinical suspicion for candidiasis in the setting of vaginal 172 
steroid use, consider obtaining a KOH and fungal culture and initiating treatment with antifungal 173 
medications. 174 
Insertion of an intravaginal device as early as possible may prevent adhesions and stenosis in 175 
those with visible disease.79 Intravaginal devices should be used regularly until complete healing 176 
of lesions and may remain in place for up to 24 hours before being replaced. In patients 177 
uncomfortable with using an intravaginal device, medications can be applied twice daily with a 178 
vaginal applicator. The role of intravaginal devices in patients without visible disease is 179 
uncertain (median 5, DI 0.49).  180 
Menstrual suppression may reduce the risk of vaginal adenosis and endometriosis and can be 181 
considered in women with severe genital mucosal involvement.83,85 Topical estrogen has been 182 
shown to promote healing in other vulvar dermatoses and burns and should be considered as 183 
adjuvant therapy. 90-94 184 
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Urinary catheters are recommended to decrease pain with urination, prevent urinary obstruction, 185 
and monitor fluid balance.11,80 They should be removed as soon as complete healing occurs and 186 
the patient passes a voiding trial. The SDH expert anel recommends topical lidocaine to 187 
minimize pain with urinary catheter and vaginal devic  insertion. 188 
 189 
Pain management  190 
Mucocutaneous pain is a key feature of SJS/TEN, occurring in ~ 90% of patients and associated 191 
with physical and psychological burden and prolonged hospital stay. It is exacerbated by 192 
physical activity, procedures, and dressing changes.95  193 
Pain management should be individualized according to pain level and patient comorbidities. 194 
Pain level should be evaluated every 4 hours using visual or numeric analog scales.96 195 
Wound care strategies that minimize dressing changes are associated with reduced pain.37,39,97 196 
Acetaminophen may be sufficient for treatment of mild pain. However, opioid therapy is 197 
frequently indicated. Oral synthetic opiates are helpful to control moderate pain. Morphine or 198 
fentanyl given enterally, by intravenous bolus, patient-controlled analgesia, or via infusion, may 199 
be necessary for more severe pain.98 Low-dose ketamine infusions may be considered as an 200 
alternative or adjuvant therapy for pain in SJS/TEN.96,99,100 Gabapentin and pregabalin help 201 
address neuropathic pain and may decrease opioid consumption in both the acute and healing 202 
phases.101-104 Non-steroidal anti-inflammatory drugs should generally be avoided due to their 203 





Infection surveillance 208 
Infections have been reported in up to 85% of patients with SJS/TEN,105 and sepsis is the most 209 
common cause of death.106-109 Exposed dermis facilitates bacterial colonization, leading to 210 
increased infection risk and impaired re-epithelialization.11  211 
The skin should be monitored frequently for signs of infection, such as increasing skin pain.11 212 
Confusion, hypotension, reduced urinary output, and reduced oxygen saturation may indicate 213 
systemic infection.106,110 In patients in whom infection is suspected, bacterial swabs should be 214 
obtained. Slow-healing sites with erosions or vesicl  may indicate HSV super-infection, 215 
particularly in genital and oral sites; viral swabs should be obtained in such cases.11 The SDH 216 
expert panel did not favor routine performance of skin cultures to guide antimicrobial therapy. 217 
Severe ear-nose-throat (ENT) involvement has been associated with pulmonary infection.111 218 
Evaluation using nasal fiberoptic endoscopy should be considered when dysphonia or dyspnea 219 
are present. For intubated patients, there was disagreement and uncertainty (median 5, DI > 1.02) 220 
regarding the need of routine fiberoptic bronchoscopy t  obtain bronchoalveolar lavage 221 
specimens for culture and sensitivity testing, in the absence of signs of infection.112 222 
Hand hygiene and hospital infection control measures should be followed to prevent infection.  223 
Prophylactic antibiotic coverage in the absence of pr ven or suspected infection may select for 224 
resistant organisms and contribute to increased mortality.113 Antibiotic-therapy should be tailored 225 
to culture data12,113,114 and local antibiogram.115 Data suggest Staphylococcus aureus, 226 
Pseudomonas aeruginosa, and Enterobacteriaceae organisms are the most common causes of 227 
blood stream infection in SJS/TEN.106  228 
Patients with SJS/TEN may develop neutropenia, especially in severe cases.116,117 The role of 229 
recombinant human G-CSF in this setting is uncertain (median 5, DI 0.32).118,119  230 
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Fluid management and electrolytes  231 
Electrolytes abnormalities occur in approximately 20% of patients with SJS/TEN.95 Due to 232 
extensive skin failure, patients may have large insnsible losses.11 Oropharyngeal lesions 233 
contribute to decreased oral intake. Electrolytes can be lost in blister fluid, which is rich in 234 
sodium, potassium, and chloride.13 Hypophosphatemia is also common.13 Fluid balance and 235 
electrolytes should be monitored daily to ensure adequate correction during treatment.120 236 
Fluid resuscitation in SJS/TEN is adapted from the management of burn patients, though fluid 237 
losses, in general, are less.121 Current evidence supports the use of crystalloid fr resuscitation, 238 
though there are no prospective data to guide fluidselection.121-123 Evidence regarding colloid 239 
fluids and albumin is controversial,121,124-127 and their use was considered uncertain by the expert 240 
panel (median 6, DI 0.65). Appropriate calculation of fluid resuscitation volume based on the 241 
percent of detached skin was also uncertain (median 5, DI 0.55) .14,123,126 The expert panel 242 
recommended resuscitation be guided by physiologic parameters, with a target urine output of 243 
0.5 – 1 mL/kg/hr.25,128,129 244 
 245 
Nutrition and stress ulcer prophylaxis  246 
Caloric requirements in SJS/TEN are increased.11 Caloric intake should be 30-35 kcal/kg.13 In 247 
patients unable to eat, a nasogastric tube should be used to provide enteral nutrition unless there 248 
is involvement of the nasopharyngeal mucosa.130-132Enteral nutrition is preferable to prevent 249 
stress ulcer formation and infectious complications.133 If adequate nutritional requirements 250 
cannot be met enterally, parenteral nutrition can be used to supplement deficiencies,99,134 251 
however it has been associated with higher mortality rates.135  252 
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Hyperglycemia is common in SJS/TEN and is associated with increased mortality, therefore, 253 
careful glucose monitoring to ensure adequate glycemic control is recommended.131 Tight 254 
glycemic control regimens (serum glucose 80–110 mg/dl) have been associated with increased 255 
hypoglycemic events and mortality among adults in the ICU; thus, glycemic control regimens 256 
maintaining glucose levels between 110 -180 mg/dl are preferable.136-139 257 
In patients receiving enteral nutrition, pharmacologic stress ulcer prophylaxis (SUP) is not 258 
recommended based on studies performed in ICU patients.140-142  259 
 260 
Airway management 261 
Patients with SJS/TEN may experience sloughing of the respiratory tract epithelium which 262 
cannot be predicted by the extent of cutaneous involvement.11 Chest x-ray and arterial blood gas 263 
measurement should be obtained as part of the baseline evaluation.16,143-145 Appropriate 264 
pulmonary toilet and positioning may help keep the upper airway clear.13 Attention should be 265 
paid to the nose to maintain a clear respiratory passage. 266 
Patients with hypoxemia, dyspnea, or tachypnea should undergo fiberoptic bronchoscopy to 267 
evaluate the extent of bronchial involvement while minimizing iatrogenic trauma.145,146 268 
Pulmonary function testing and computed tomography scanning are indicated in those with 269 
ongoing respiratory symptoms.14,147 270 
Patients with SJS/TEN may experience airway compromise requiring intubation and early 271 
tracheostomy (before ventilator day 10) prior to the onset of respiratory failure, predicted by oral 272 
mucosal involvement and initial BSA of 70% or more, progression of BSA from hospital day 1 273 
to hospital day 3 by 15% or more, neurologic diagnosis preventing airway protection, or 274 
documented airway involvement on direct laryngoscopy.148 Improved survival is attributed to 275 
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aggressive wound care after airway protection. Ventilation strategies should mimic those used in 276 
acute respiratory distress syndrome, such as low tidal volume149 and early prone 277 
positioning.144,150 278 
 279 
Anticoagulation  280 
Patients with SJS/TEN are at increased risk of venous thromboembolism. Prophylaxis with low 281 
weight molecular heparin is recommended.151-154 Patients who are bleeding or at high risk of 282 
major bleeding should receive graduated compression stockings or intermittent pneumatic 283 
compression instead.152,154 Early mobilization of patients should be encouraged.155 284 
 285 
LIMITATIONS AND CONCLUSION  286 
These guidelines address supportive care treatment options for adult patients with SJS/TEN. 287 
Systemic treatment options, management of sequelae, and considerations in special populations 288 
(e.g., pediatric, pregnant) will be addressed in future guidelines. Judgment regarding the 289 
appropriateness of any specific therapy lies with the treating clinician. Future studies will 290 
necessitate revisions and updates to these recommendatio s. 291 
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Table 1. Clinical Question  
What supportive care treatment strategies are safe and effective for adult patients with SJS, SJS-
TEN overlap, or TEN? 
1. Hospital setting and care team 
2. Wound care 
3. Ocular care 
4. Oral care 
5. Urogenital care 
6. Pain management 
7. Infection surveillance 
8. Fluid and electrolyte management 
9. Nutrition and stress ulcer prophylaxis 
10. Airway management 
11. Anticoagulation 
SJS, Steven-Johnson syndrome; TEN, toxic epidermal necrolysis
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Table 2. Recommendations 
 





Hospital setting and care team 
Management of patients with SJS/TEN requires a multidisciplinary team that may include dermatology, 
intensive care, pulmonology, ophthalmology, otorhinolaryngology, gynecology, urology, nephrology, plastic 
surgery, nutrition, nursing, psychology/psychiatry, and other fields. 
4 D (GPP) 0.00 9.0 
Dermatologists are experts in the disease state of SJS/TEN and should directly participate in the 
management of such patients. 
4 D (GPP) 0.00 9.0 
Staff should have specific training in the care of patients with SJS/TEN. 4 D (GPP) 0.13 9.0 
Chronic conditions and comorbidities play a significant role in the mortality of SJS/TEN patients and the 
need for specialized care, and hospital transfers should take into account these comorbidities. 
3 C 0.00 9.0 
Medical or burn ICU settings of care for SJS/TEN patients are recommended. 2-/3 D 0.00 9.0 
SJS/TEN patients must be cared for in a private room. 3 D 0.13 9.0 
Patient rooms should be controlled for humidity. 4 D 0.26 7.5 
Sterile sheets should be obtained and used for patient bedding, where available 4 D 0.65 8.0 
At least one nurse should take care of one SJS/TEN patient (at least 1:1 ratio). 4 D 0.32 8.0 
Wound care 
Determine % BSA of epidermal detachment (only skin that is already necrotic, detached, or skin with 
positive Nikolsky sign). 
3 D 0.06 9.0 
Avoid unnecessary wound manipulation by limiting the number of dressing changes.  3 D 0.13 8.0 
Use an air-fluidized bed to minimize friction. 3 D 0.15 8.0 
Gently cleanse all areas with sterile water, normal saline, or dilute chlorhexidine (0.05%) solution with 
dressing changes. 
4 D  0.26 8.0 
The detached and detachable epidermis should be left in place as a biological dressing. 4 D (GPP) 0.13 8.0 
Lyse large or painful bullae for comfort only. 4 D (GPP) 0.20 8.0 
Wound debridement of necrotic skin is not recommended. 4 D (GPP) 0.82 7.0 
Apply topical emollients such as petroleum jelly on the entire epidermis. 3 D 0.13 8.5 
Apply non-adherent sterile dressings to denuded skin. 3 D 0.13 9.0 
Select non-adherent silver-impregnated primary dressings for optimal moisture retention and antibacterial 
properties. 
2+/3 D 0.59 6.5 
Apply secondary dressing to absorb exudate. 3 D 0.37 7.0 
Ocular care 
Patients thought to have SJS/TEN should be examined by an ophthalmologist as part of the initial 
assessment. 
4 D (GPP) 0.00 9.0 
Patients should be examined at least every 24 hours until it is clear there is no worsening, and thereafter the 
frequency of follow-up should be determined on a case-by case basis. 
4 D (GPP) 0.13 9.0 
Educate the appropriate staff regarding the need for immediate ophthalmologic evaluation of all SJS/TEN 4 D (GPP) 0.00 9.0 
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patients and the proper application of topical ocular medications (drops and ointments). 
The entire ocular surface should be examined daily- eyelid skin, eyelid margin, conjunctiva, and cornea. The 
eyelids should be everted, and the eyes rotated to look for forniceal and tarsal conjunctival epithelial defects 
and early symblephara. 
4 D (GPP) 0.13 8.0 
Fluorescein staining should be done i  all patients. 4 D 0.65 6.5 
Resting eyelid position should be assessed for lagophthalmos. 4 D 0.37 8.0 
Grade the ocular exam findings to facilitate medical decision making (eAppendix5). 3 D 0.65 7.0 
Consider amniotic membrane transplantation (AMT) during the initial evaluation of any patient thought to 
have SJS/TEN and at each follow-up exam during the acute phase. 
1+/2+ B 0.13 8.0 
Offer AMT to patients with moderate to severe conjunctival injection, significant conjunctival epithelial 
defects (especially the eyelid margin, tarsal conjunctiva, fornices), significant corneal epithelial defects or 
membranes / pseudo-membranes. 
1+/2+ B 0.13 8.0 
AMT is ideally performed within 5 days of onset but may be offered later. 1+/2+ B 0.13 8.0 
Amniotic membrane should cover the entire ocular surface. 1+/2+ B 0.00 8.0 
Apply artificial tears every 1-2 hours for any patient with any ocular surface inflammation. 4 D 0.13 8.0 
Apply ophthalmic ointment to the eyelid margin every 2-24 hours. 4 D 0.13 8.0 
Eye drops containing preservatives should be avoided. 4 D 0.48 8.0 
Apply a moisture chamber over the eyes for lagophthalmos. A facemask or moist occlusive dressing may be 
used for this purpose. 
4 D 0.56 8.0 
Rinse the eyes every 2-24 hours with sterile saline. 4 D 0.16 7.5 
Remove/lyse adherent debris and membranes daily. 4 D 0.16 8.0 
Apply a topical anesthetic (e.g. proparacaine or tetracaine) if needed. 4 D 0.12 8.0 
Apply a corticosteroid containing ointment to the ey lid margin and eyelashes at least once daily and a 
corticosteroid drop to the ocular surface at least twice daily for any patient with any ocular surface 
inflammation. 
2- D 0.59 8.0 
If there is clinical suspicion of infectious conjunctivitis, obtain a bacterial (and consider a fungal) culture of 
the ocular surface and begin application of a topical broad-spectrum antibiotic (4th generation quinolo e 
commonly used). 
4 D 0.00 8.0 
Avoid chloramphenicol drops and tetracycline containing ointment, as these have been associated with late 
complications, particularly dry eyes. 
3 D 0.65 8.0 
Oral Care 
The mouth should be examined as part of the initial assessment of a patient with SJS/TEN. 4 D (GPP) 0.00 9.0 
Daily oral exam is required during acute illness. 4 D (GPP) 0.00 9.0 
Have a low threshold for HSV PCR, bacterial, and fungal cultures if infection is suspected. 4 D (GPP) 0.00 9.0 
Petrolatum ointment should be applied on the lips immediately, and then every 2 hours throughout the acute 
illness. 
3 D 0.29 8.0 
Viscous lidocaine 2%, 15 ml per application, can be us d every three hours (and prior to cleanses) as an oral 
rinse to control pain. 
3 D 0.13 8.0 
Clean the mouth daily with warm saline mouthwashes or an oral sponge, sweeping the sponge gently in the 
labial and buccal sulci to reduce the risk of fibrotic scars and prevent buildup of hemorrhagic crust. 
3 D 0.13 8.0 
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An antiseptic oral rinse should be used twice daily to reduce bacterial colonization of the mucosa. 3 D 0.65 6.5 
A topical steroid (ultrapotent) ointment can be applied up to 4 times a day during the acute phase. 3 D 0.58 8.0 
Consider diluted chlorhexidine digluconate mouthwash (2-3 times daily). 3 D 0.37 7.0 
Consider the use of oral coating agents for pain reduction in patients with oral mucosal involvement. 4 D 0.13 8.0 
Urogenital care 
Examine the urogenital tract as part of the initial assessment of a patient with SJS/TEN. 4 D (GPP) 0.00 9.0 
Urogenital exam should ideally be performed by a gynecologist, urologist, or urogynecology specialist. 4 D (GPP) 0.13 8.0 
Daily exam is required during the acute illness. 4 D (GPP) 0.13 8.0 
If there is clinical suspicion for vaginal candidiasis in the setting of vaginal steroid use, consider obtaining a 
KOH and fungal culture and beginning treatment with antifungal medications.  
4 D (GPP) 0.13 8.0 
During the acute phase of the disease, the vulvar/urogenital skin/mucosa should be coated with an ointme t 
and/or ointment gauze to help reduce pain, reduce adh sion formation, and facilitate healing. 
3 D 0.13 8.0 
An intravaginal device such as a dilator/tampon/vagin l mold/roll of gauze covered in a lubricated cond m 
can be utilized to treat vaginal disease. 
3 D 0.13 9.0 
Intravaginal devices may be left in place for no longer than 24hrs, at which time they should be replaced. 3 D 0.03 8.0 
Even for virginal patients, use of a small mold or a condom-covered tampon should be encouraged if the 
patient is emotionally and physically comfortable with the regimen. 
4 D 0.65 7.0 
Patients uncomfortable with using an intravaginal device, can apply medication twice daily with a vaginal 
applicator. 
4 D 0.06 8.0 
Topical anesthetics (i.e., lidocaine 5% ointment) can be used at the vaginal introitus, once open sores have 
healed, to reduce discomfort with use of the vaginal dil tors. 
3 D 0.01 8.0 
It is at the provider’s discretion to use either a non-steroidal ointment (i.e., petrolatum jelly) with 
reapplication as frequently as necessary (2-4x daily) to maintain barrier protection and/or consider 1-2x 
daily application of a high potency steroid ointment if active inflammation is observed, with the cavet that 
consideration for tapering of steroid use should be based on clinical improvement. 
3 D 0.00 8.0 
Consider the medication on the dilator can be changed to, or alternated with, estrogen cream to help promote 
healing of the vaginal mucosa.  
4 D 0.55 7.0 
Consider menstrual suppression to reduce discomfort and possibly to decrease the risk of vaginal adenosis. 3 D 0.69 8.0 
Consider division of any fine [vaginal] adhesions to prevent the development of thick fibrous bands that
could lead to problems inserting tampons and during sexual intercourse later in life. 
3 D 0.22 8.0 
Consider urinary catheters to decrease pain with urnation, prevent urinary obstruction, and monitor fluid 
balance. 
3 D 0.13 8.0 
Pain management 
Evaluation and treatment of pain is a priority in theacute phase, especially during wound management. 4 D (GPP) 0.00 9.0 
Pain should be evaluated on a 4-hourly basis. 4 D (GPP) 0.13 9.0 
A validated pain tool should be used to assess pain in all conscious patients at least once a day. 4 D (GPP) 0.13 9.0 
If  the score is mild, pain control with acetaminophen should be introduced. 3 D 0.00 8.0 
If acetaminophen is not enough, oral synthetic opiates such as tramadol should be considered. 3 D 0.23 8.0 
If the pain score is moderate to severe, then morphine or fentanyl should be delivered enterally, by PCA, or 
by infusion. 
3 D 0.13 8.0 
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Procedures such as dressing changes and bathing may require additional pain control. 3 D 0.00 9.0 
Consider adding low dose ketamine infusions. 3 D 0.65 6.5 
Consider adding abapentin or pregabalin. 3 D 0.65 7.0 
NSAIDs should be avoided due to renal or gastric injury. 3 D 0.35 7.0 
Infection surveillance 
Hand hygiene and other infection control measures should be strictly applied. 3 D (GPP) 0.00 9 
Patients should be monitored carefully for signs of systemic infection, such as confusion, hypotension, 
reduced urine output and reduced oxygen saturation. 
3 D  0.00 9 
Cutaneous infection may be accompanied by increase in skin pain. 3 D 0.13 8.5 
Consider activation of HSV in eroded or vesicular areas which are slow to heal, particularly in genital and 
oral sites. Take viral swabs if herpes virus infection is suspected. 
3 D 0.00 9 
In patients with diarrhea who are immobile, consider a fecal management system to prevent f cal soiling of 
wounds. 
3 D 0.13 8.5 
Prophylactic antibiotic treatment is not recommended. 4 D 0.13 8.5 
Administer systemic antibiotics only if there are clini al signs of infection. The choice of systemic antibiotic 
should be guided by local microbiological resistance patterns. 
3 D 0.13 9 
Severe ENT involvement is significantly associated with pulmonary infection. ENT evaluation using nasal 
fiberoptic endoscopy should be suggested when dysphonia or dyspnea are present. 
3 D 0.16 8.0 
Fluid and electrolyte management 
Peripheral catheters preferred for vascular access with implantation in uninjured skin and fixed with non-
adhesive dressings. 
3 D 0.13 9 
Change peripheral venous cannulas every 48 hours if possible. 3 D 0.65 7 
Monitor electrolytes and fluid balance daily. 4 D (GPP) 0.00 9 
Consider invasive fluid balance monitoring with Foley catheter. 3 D 0.33 8 
Fluid administration should be titrated to urine output (0.5-1 ml/kg/hr). 3 D 0.16 8 
Nutrition and stress ulcer prophylaxis 
Maintain adequate nutrition orally; utilize nasogastric tube if necessary. Enteral feeding reduces stres  ulcers 
and reduces bacterial translocation and enterogenic infe tion. 
3 D 0.13 9 
Supplement enteral nutrition with parenteral if intake via the enteral route is insufficient to meet caloric 
needs. 
3 D 0.39 8 
Avoid nasogastric tube placement if there is involvement of the nasopharyngeal mucosa. 3 D 0.37 7 
Deliver daily caloric requirement of 30-35 kcal/kg. 3 D 0.33 8 
Maintain close glycemic control. 3 D (GPP) 0.03 8 
In patients receiving enteral nutrition, pharmacologic stress ulcer prophylaxis is not recommended. 4 D (GPP) 0.65 8 
Pharmacologic stress ulcer prophylaxis with PPIs should be limited to patients at high risk for clinically 
important bleeding (respiratory failure, coagulopathy, liver disease, use of renal replacement therapy, three 
or more co-existing diseases). 
4 D (GPP) 0.16 8 
PPIs should be used over H2 receptor antagonists (due to decrease in GI bleeding events). 4 D (GPP) 0.5 7.5 
Airway management 
The nose should be examined as part of the initial assessment of a patient with SJS/TEN. 4 D (GPP) 0.13 9 
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Daily nasal exams are required during acute illness. 4 D (GPP) 0.07 8 
Pulmonary care includes normal saline aerosols, bronchial aspiration and postural drainage by turning the 
patient to different sides. 
4 D 0.11 8 
Severe ENT involvement is significantly associated with pulmonary infection. ENT evaluation using nasal 
fiberoptic endoscopy should be suggested when dysphonia or dyspnea are present. 
3/4 D 0.16 8 
Chest X-ray and arterial blood gases should be obtained upon admission for baseline respiratory function 
assessment. 
3/4 D 0.65 7 
Patients with ongoing respiratory symptoms should be closely monitored with pulmonary function testing 
and high-resolution computed tomography (CT) scanning. 
3 D 0.37 8 
Fiberoptic bronchoscopy should be undertaken in patients with respiratory symptoms and hypoxia. 3 D 0.00 8 
Bronchoscopy should be done by an experienced technician due to risk of post-instrumental endobronchial 
bleeding. 
3 D 0.13 8 
Consider intubation and early tracheostomy in patients with oral involvement AND one of the following: 
• Initial BSA 70% or more 
• Progression of BSA involved from DOH1 to DOH3 > 15% 
• Underlying neurologic diagnosis prevents airway protection 
• Documented airway involvement on direct laryngoscopy 
3 D 0.40 7 
Ventilation strategies should mimic ARDS management guidelines (low tidal volume and early prone 
positioning). 
4 D 0.65 7 
Anticoagulation 
Immobile patients should receive low molecular weight heparin. 4 D (GPP) 0.07 8 
For acutely ill patients at increased risk of thrombosis who are bleeding or at high risk for major bleeding, 
mechanical thromboprophylaxis with graduated compression stockings or intermittent pneumatic 
compression is recommended. 
4 D (GPP) 0.16 8 
*For level of evidence and grade of recommendation calculation see eAppendix2. GPP, good practice point. A GPP is a recommendation for best 
practice based on the experience of the guideline dev lopment group. 
**Statements were appraised on a Likert scale of 1 (strongly disagree) to 9 (strongly agree), medians and disagreement indexes (DI) were 
calculated for each statement. Items with a DI≤1 and a median≥6.5 were deemed appropriate and included in the guidelines, and all other items 
were not included as recommendations. (eAppendix4) 
SJS, Steven-Johnson syndrome; TEN, toxic epidermal necrolysis; BSA, Body Surface Area; DI, disagreement index; DOH, Day of 
hospitalization; ENT, Ear-Nose-Throat; ICU, Intensive Care Unit; NSAIDs, Non-steroidal anti-inflammatory drugs; PCA, patient-controlled 
analgesia; PPI, proton pump inhibitor. 
 
